Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Lefer
Lsu Health Sciences Center, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sulfagenix, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Lefer has disclosed ownership in a startup company, Sulfagenix, Inc. Dr. Lefer holds a (b)(4) ownership and serves on the Scientific Advisory Board. Sulfagenix, Inc. seeks to develop hydrogen sulfide based therapeutics for a number of cardiovascular diseases. Dr. Lefer will serve on the Internal Steering Committee for Dr. Daniel Kapusta’s COBRE grant titled “Mentoring in Cardiovascular Biology.” The grant provides infrastructure, core lab support, and collegial scientific environment necessary to mentor outstanding investigators and foster collaborations in cardiovascular biology at LSUHSC-NO. Dr. Lefer could also potentially serve as a mentor to an investigator through this COBRE grant.
Mentoring in Cardiovascular Biology
Cardiovascular disease is the leading cause of death in both men and women in the United States, and is a major cause of death throughout the world. This Center of Biomedical Research Excellence sponsors research and training that involves in vitro analysis of molecular processes that alter vascular cell function and animal models of disease progression, which ultimately guide translational research to understanding how cellular and molecular changes lead to cardiovascular disease progression in humans
Filed on February 20, 2015.
Tell us what you know about David Lefer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Lefer”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Lefer | Lsu Health Sciences Center | Conflict of Interest | Exscien and NovoMedix | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.